Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.

NCT05501054 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Ipilimumab
DRUG: Nivolumab
DRUG: Ciforadenant

Sponsor

M.D. Anderson Cancer Center